TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive Fewer, Larger RT Doses Cut Recurrence Of Early Breast Cancer, UK Study Finds June 29, 2007
TCL Archive NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner. June 2, 2006
TCL Archive As For-Profits Provide Phase I Studies, NCI Seeks to Look Deeper and Learn More April 6, 2012
